Navigation Links
ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
Date:9/19/2011

her validate the Aestus approach to drug discovery."

ALS is a progressive neurodegenerative disease that causes muscle weakness, disability and eventually death. An estimated 30,000 people are living with ALS in the United States and approximately 450,000 worldwide. There are currently no effective treatments that significantly alter the disease's relentless nature.  Tragically, the average person survives only 3-5 years following a diagnosis with ALS. In addition to the current lack of effective treatments for ALS, there is little known about what causes the disease in the vast majority of cases not directly caused by known inherited, genetic mutations.

About ALS TDI
The mission of the ALS Therapy Development Institute (ALS TDI) is to develop effective therapeutics that slow or stop amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), as soon as possible. Focused on meeting this urgent unmet medical need, ALS TDI executes a robust discovery program, while running the world's largest efforts to preclinically validate potential therapeutics; including small molecules, protein biologics, gene therapies and cell-based constructs. The world's first nonprofit biotech, ALS TDI has developed an industrial-scale platform that allows for the development and testing of dozens of potential therapeutics each year. Built by and for patients, the Institute is the world's only nonprofit biotechnology company with more than 30 professional scientists. In addition, the Cambridge, Massachusetts based research Institute collaborates with leaders in both academia and industry to accelerate ALS therapeutic development. For more information, please visit us online at www.als.net.

About Aestus Therapeutics, Inc.
Aestus Therapeutics Inc. is a translational medicine company focused on serious neurological diseases. Capitalizing on genomic data analysis to discover novel links between these diseases and
'/>"/>

SOURCE ALS Therapy Development Foundation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Immune Deficiency Foundation Launches Free Accredited Course for Nurses About Primary Immunodeficiency and Immunoglobulin Therapy
2. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
3. Randomized Study Comparing Cell Therapeutics OPAXIO (Paclitaxel Poliglumex) and Radiotherapy to Standard of Care Temozolomide and Radiotherapy Treatment Open for Enrollment
4. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
5. Penn Receives $10 Million to Create Center for Orphan Disease Research and Therapy
6. Genethon and Childrens Hospital Boston Get FDA approval for a Wiskott Aldrich Gene Therapy Trial
7. RegenoCELL Announces That Patients Can Be Treated With Its Autologous Stem Cell Therapy in Greece
8. FDA Approves Dendreons Los Angeles Cancer Immunotherapy Manufacturing Facility
9. Celladon Corporation Announces Publication of Advanced Heart Failure Clinical Trial Results With MYDICAR® Enzyme Replacement Therapy in the Journal Circulation
10. Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy
11. Adeona Announces Positive Alzheimers Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 Proove Biosciences , the ... presenting research on the association between specific genes and ... Psychiatric and Mental Health Congress’ 27th Annual Scientific ... on the theme of ‘Embracing Change.’ Mental health, and ... landscape. From the challenges presented by the Affordable Care ...
(Date:9/23/2014)... San Jose, California (PRWEB) September 23, 2014 ... – Agricultural biotechnology is gaining steady popularity the ... sophisticated plant breeding techniques. Growth in the marketplace ... Genetically Modified (GM) crops in developing countries. Several ... 30% of under-nourished population, have already implemented genetically ...
(Date:9/23/2014)... This is a professional and ... Isopropanol (IPA) industry. The report provides a basic ... industry chain structure. Global market analysis and Chinese ... on history, developments, trends and competitive landscape of ... Chinese situation is also offered. , The report ...
(Date:9/23/2014)... Marktech Optoelectronics has introduced the MTE280xxx series, its ... 280 nm wavelength range. This series joins Marktech’s current ... to 405nm. These new devices are suitable for applications ... Mark Campito, Marktech’s CEO states that “what makes this ... that we offer it in one of the largest ...
Breaking Biology Technology:Proove Biosciences Will Be Exhibiting New Genetic Research at the 27th Annual US Psych Congress Scientific Program 2Proove Biosciences Will Be Exhibiting New Genetic Research at the 27th Annual US Psych Congress Scientific Program 3Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 4(IPA) Isopropanol Industry International & China Development Trend Analysis Now Available at DeepResearchReports.com 2(IPA) Isopropanol Industry International & China Development Trend Analysis Now Available at DeepResearchReports.com 3Marktech Introduces its New Line of Deep UV Emitters 2
... Split Effective at Close of Business Today ... - VGNI Stock Symbol to Change to VRGE, PLANTATION, ... majority-owned subsidiary,of Viragen, Inc. (OTC Bulletin Board: VRAI), today announced that ... outstanding common stock,will become effective at the close of business today, ...
... 4, Dow AgroSciences LLC, a wholly owned subsidiary,of ... and Exelixis Plant Sciences, a,wholly owned subsidiary of ... the companies have signed a major research collaboration ... Dow AgroSciences,affiliate Agrigenetics Inc. The agreement is focused ...
... forum for the global pharma/biotech industries, Pharmaceutical Manufacturing and Biotechnology Middle ... ... DUBAI, United Arab Emirates, Sept. 4 The Middle East,market for pharmaceutical ... growth in double digits. The market,drivers are: -- Dubai is the ...
Cached Biology Technology:Viragen International to Reverse Split Its Common Stock 2Viragen International to Reverse Split Its Common Stock 3Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation 2Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation 3
(Date:9/23/2014)... National Institutes of Health will award funds to support ... Screening program to improve ways of predicting drug safety ... refine existing 3-D human tissue chips and combine them ... functions of the human body. Led by the National ... support 11 institutions at $17 million in 2014 with ...
(Date:9/23/2014)... announced today that the Company has secured $21 million ... be used to expand the Company,s cancer immunotherapy pipeline ... investor Yuan Capital led the round, with participation from ... Ventures, Suma Venture and Harbinger Venture Capital. , ... fully-human antibodies engineered to mimic the functions of a ...
(Date:9/23/2014)... are the same ones that were used 50 years ago. ... disease, which causes nearly 25 million people in the United ... best to take a deep breath. , But finding ... what works for one person doesn,t necessarily work for another, ... candidates often fail to mimic human responses costing tremendous ...
Breaking Biology News(10 mins):NIH funds next phase of Tissue Chip for Drug Screening program 2NIH funds next phase of Tissue Chip for Drug Screening program 3NIH funds next phase of Tissue Chip for Drug Screening program 4Airway muscle-on-a-chip mimics asthma 2Airway muscle-on-a-chip mimics asthma 3
... a great health threat, especially since routine smallpox ... treatment currently exists. In the February 1 issue ... and colleagues from Harvard Medical School propose a ... of signaling mediated by the smallpox growth factor ...
... research on prions, the infectious proteins behind "mad cow" disease ... prions in one species to infect other species depends on ... prion. Two studies on the topic appear in the 8 ... suggests that prions from one species rarely infect other species, ...
... tweaked to absorb more contaminants, researchers found that the ... results raised hopes that the plants might become a ... new research findings, published Feb. 1 in the journal ... of the Indian mustard plant, Brassica juncea, absorbed two ...
Cached Biology News:Fibril Shape Is The Basis Of Prion Strains And Cross-species Prion Infection 2Fibril Shape Is The Basis Of Prion Strains And Cross-species Prion Infection 3Transgenic plants remove more selenium from polluted soil than wild plants, new tests show 2Transgenic plants remove more selenium from polluted soil than wild plants, new tests show 3Transgenic plants remove more selenium from polluted soil than wild plants, new tests show 4
Recombinant Rat Leptin, Ultra Pure...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
quantitation of phosphatase activity, evaluation of hits and leads from HTS...
Biology Products: